3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
5
Recurrence
2
Esophageal Neoplasms
2
Solitary Fibrous Tumor, Pleural
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
MET Positive
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Carboplatin
340
Cisplatin
238
Paclitaxel
203
Radiotherapy
195
Pemetrexed
187
Docetaxel
169
Gemcitabine
157
pembrolizumab
141
Erlotinib Hydrochloride
107
Etoposide
99
Magnetic Resonance Spectroscopy
93
Bevacizumab
91
Specimen Handling
76
Nivolumab
73
Radiosurgery
72
durvalumab
69
Vinorelbine
54
osimertinib
53
Gefitinib
49
Drug Therapy
49
atezolizumab
42
Irinotecan
42
Radiation
40
Topotecan
39
Biopsy
39
Standard of Care
38
Cyclophosphamide
38
Cetuximab
35
Blood Specimen Collection
33
Taxes
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lung Neoplasms
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts